Panaxia Pharmaceutical Industries specializes in the research, development, and manufacturing of medical cannabis. The company's goal is to align medical cannabis with formulation technologies and the highest available pharmaceutical standards. Panaxia currently manufactures a variety of standardized medical cannabis products including sublingual and oral tablets, metered-dose inhalers, creams, and suppositories.
The company's products, manufacturing facility, and production processes are subject to stringent quality assurance procedures. Panaxia is part of the Panaxia Medical Devices and Pharmaceuticals Group. Panaxia's R&D center is located in Israel and is managed by senior scientists and graduates of the Weizmann Institute of Science.
Panaxia offers more than 600 medical products in over 30 international markets to treat a wide range of symptoms and conditions.
Cumulative Funding Raised Over Time ($)
Employees Over Time
Panaxia Climate Tech relevance
null
Latest News
No Data, yet.
Sorry, no content found under this section.
Jan 29, 2024
www.themarker.com
עמוס לוזון נסוג - ופנאקסיה תימכר למייסד תמורת מחיקת החוב
#Unknown
Oct 6, 2022
www.prnewswire.com
Panaxia and Neuraxpharm to enter new medical cannabis markets in Europe
#Partners #Expand
May 19, 2022
www.prnewswire.com
Panaxia announces production license of medical cannabis products in Malta
#Customers #Partners
Jan 3, 2022
www.prnewswire.com
Panaxia's facility in Malta granted EU-GMP Standard
#Partners #Customers
Nov 3, 2021
www.prnewswire.com
From vision to reality: Panaxia and Neuraxpharm are the world's first companies to sell medical cannabis extracts for inhalation in Europe